((Rami Komrokji, MD))
In a study conducted at my institution that focused on IPOP administration with VYXEOS, patients were excluded from the study if they had increased risk for tumor lysis including white count greater than 50,000, increased creatinine/uric acid, active cardiopulmonary symptoms, ECOG greater than 2, or lacked a caregiver or were unable to reside within 60 minutes of the treating facility.
In this study, 22 patients received a full induction course of VYXEOS.
Of these, 14 received induction in an IPOP setting, and 13 of those patients were admitted for continued care on Day 6, as planned.
In this study, the majority of patients were able to receive VYXEOS induction in the outpatient setting followed by a planned admission.
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION